Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients.

The new report highlights several barriers to CGT use, including cumbersome referral processes, high price tags, complex logistics, and uncertainties around reimbursement. | Image Credit: Treecha - stock.adobe.com

CGTs Have Potential to Transform Care, but Challenges Persist

By Rose McNulty

May 14th 2025

Despite holding promise in a range of disease states, a variety of challenges prevent cell and gene therapies (CGTs) from more widespread use, according to a new report from Cardinal Health.

Quantitative magnetic resonance imaging seemed to show that delandistrogene moxeparvovec protects muscle from progressive damage in DMD. | Image credit: OlegKachura - stock.adobe.com

Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression

By Rose McNulty

May 14th 2025

Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.

Using Data Exchange to Improve Quality Reporting, Target Outreach, and Reduce Cost

By Barbara Rubino, MD
Chelsea Hart-Connor, MA

Todd A. May, MD

May 13th 2025

Covered California and Health Net’s novel data exchange initiative significantly improved quality measurement and potentially reduced costs by more than $640,000.

Health Outcomes Under Full-Risk Medicare Advantage vs Traditional Medicare

By Kenneth Cohen, MD
Boris Vabson, PhD

Jennifer Podulka, MPAff
Omid Ameli, MD, DrPH
Kierstin Catlett, PhD
Nathan Smith, PhD
Megan S. Jarvis, MS
Jane Sullivan, MPH
Caroline Goldzweig, MD, MSHS
Susan Dentzer, MS

May 9th 2025

Physician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.

...

38 39 40 41 42

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions